Lannett niacin extended-release tablets failed dissolution specifications during stability
Lannett Niacin Extended-release Tablets, 1,000 mg, are being recalled after a stability test returned an out-of-specification low result for Stage 3 dissolution at 24 hours.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: FDA Class II recall for a failed dissolution specification, which can alter the rate of drug release and creates a risk of harm with no injuries reported.
Plain-English summary
Niacin Extended-release Tablets, USP, 1,000 mg, in 90-count bottles, distributed by Lannett Company, Inc. of Philadelphia, NDC 62175-322-46, are being recalled. The action covers 3,984 bottles.
The stated reason is failed dissolution specifications: during 12-month long-term stability testing the product was out of specification, low, for Stage 3 dissolution at the 24-hour timepoint. Dissolution testing measures how a tablet releases its active ingredient over time, which matters particularly for an extended-release formulation. The FDA classified the action as Class II.
The affected lot is 25282724A, expiry 2027/01. Distribution was nationwide within the United States.
This is a prescription medicine. Patients should not stop taking a prescribed course without medical advice; anyone holding the affected lot should contact their pharmacy or prescriber about a replacement supply.
The recalled product
- Product
- NIACIN (NIACIN)
- Brand
- NIACIN
- Manufacturer
- Lannett Company Inc.
- Category
- Drug — Extended-release tablet
- Affected units
- 3,984
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot #: 25282724A
- Exp. Date 2027/01
UPCs (1)
- 0362175320469
Distribution
Distributed nationwide across the United States.
Related recalls
Same brand · NIACIN
- ModerateNiacin extended-release tablets failed dissolution testing at 24 hours
FDA (Drugs) · 2026-06-17
- ModerateNiacin extended release tablets recalled after failing dissolution specifications
FDA (Drugs) · 2025-11-26
- ModerateNiacin extended release tablets recalled after failing dissolution specifications
FDA (Drugs) · 2025-10-29
- ModeratePrescription Niacin Tablets Recalled for Microbial Contamination
FDA (Drugs) · 2024-01-31
- HighNiacin Extended-Release Tablets Recalled for Manufacturing Microbial Contamination
FDA (Drugs) · 2024-01-31
Same manufacturer · Lannett Company Inc.
See all →- HighAmphetamine extended-release capsules contain immediate-release pellets after label mix-up
FDA (Drugs) · 2026-07-08
- LowPrimidone Tablets Recalled Due to Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27
- HighAmphetamine salt tablets recalled after bottles contained a lower strength tablet
FDA (Drugs) · 2025-09-17
- HighLisdexamfetamine 40 mg bottles recalled after being filled with 30 mg capsules
FDA (Drugs) · 2025-09-03
- HighPrescription Drug Lisdexamfetamine Dimesylate Recalled for Failed Content Uniformity
FDA (Drugs) · 2024-12-11
Same hazard · failed dissolution
See all →- ModerateNovartis Recalls Diovan Valsartan Tablets Due to Failed Dissolution Specifications
FDA (Drugs) · 2026-08-19
- LowSupernus Recalls Trokendi XR Capsules for Failed Dissolution Specifications
FDA (Drugs) · 2026-07-29
- HighAscend amlodipine and olmesartan tablets failed dissolution specifications
FDA (Drugs) · 2026-06-10
- HighMajor Pharmaceuticals memantine extended-release capsules fail dissolution specifications
FDA (Drugs) · 2026-04-22
- HighXanax XR 3 mg extended-release tablets fail dissolution specifications
FDA (Drugs) · 2026-04-15